Description
HUMANA PRESS Myeloma Therapy Pursuing The Plasma Cell 2009 Edition by SAGAR LONIAL
Therapeutic options for patients with myeloma have dramatically changed over the past 10 years. Beginning with the advances in therapy resulting from the use of high-dose therapy and autologous bone marrow or stem cell tra- plant, we have more than doubled the median survival for patients as a whole, and have now have a wealth of different biology -based treatment approaches for our patients in all disease stages. This book represents state-of-the-art information from many of the leaders in the plasma cell disorders world. Sections focusing on disease pathogenesis and biology, chemotherapy-based approaches, immune -based therapies, currently approved novel agents, developing targets, supportive care, and other plasma cell disorders provides a comprehensive collection and an excellent resource in this time of rapid change in clinical and preclinical disease knowledge. It is important to realize that these changes did not occur in a vacuum. Partnerships between academic institutions, the pharmaceutical industry, patient advocacy groups, the National Cancer Institute, community onco- gists, and ultimately our patients worked closely together to realize these advances, and to effect the radical changes in therapy we have witnessed over the past few years. This book would not have been possible without contri- tions from each of the gifted scientists and clinicians who worked tirelessly to prepare their individual chapters all the while maintaining commitment to the scientific and clinical mission of advancing care. Section 1: Biologic Considerations and Myeloma Staging and Myeloma L.T. Heffner MDEpidemiology of Multiple Myeloma A.A Langston MD and Dixil FrancisBasic Biology of Plasma Cell Dyscrasias Kenneth Anderson MD, DFCI and Marc S. RaabBiology Based Classification and Staging of Multiple Myeloma Peter Leif Bergsagel MD and Wee Joo Chng, MDThe importance of FISH and Cytogenetics R. Fonseca MD, Esteban Braggio and Michael SebagSection 2: Historical and Cytotoxic Agent based Therapies for MyelomaRole of Autologous Stem Cell Transplantation In Multiple Myeloma J.L. Harrouseau, MDMaintenance Therapy In Multiple Myeloma Jonathan L. Kaufman MD, Ronald Mihelic PharmD, and Sagar Lonial, MDTherapy for Patients not Eligible for Autologous Transplant Antonio Palumbo, MD and Sara Bringhen, MDCurrent Role of Anthracyclines in the Treatment of Multiple Myelma, A. Chanan-Khan, MD and Sikander AilawadhiSection 3: Immune Based TherapiesAllogeneic Transplantation for Multiple Myeloma Edmund K. Waller MD, PhD Fengrong Wang, MD Immunobiology and Immunotherapy of Multiple Myeloma Madhav Dhodapkar MDAntibody and other Immune based therapies for Myeloma N Munshi MD, DFCISection 4: Existing novel agents Thalidomide In Relapsed Multiple Myeloma Patients Ashraf Badros MDThalidomide: Induction Therapy S. Vincent Rajkumar MD and Francis K. Baudi, MDThe Role of Bortezomib In the Treatment of Relapsed and Refractory Multiple Myeloma Paul G. Richardson MD, DFCI, Constantine S. Mitsiades, Robert Schlossman, Irene Ghobrial, Nikhil C. Munshi and Kenneth C. AndersonBortezomib As Induction Therapy In Multiple Myeloma Patients J San Miguel MD,PhD and M.V. Mateos, MD, PhDLenalidomide In Relapsed and Refractory Multiple Myeloma Donna M. Weber MD, Sheeba K. Thomas MD, Tiffany A. Richards, MS, ANP, AOCNPLenalidomide (Revlimid (R)) For Initial Therapy of Newly Diagnosed Multiple Myeloma Shaji Kumar MDSection 5: Current and Future TargetsThe Role of Heat Shock Protein 90 As A Therapeutic Target for Multiple Myeloma Constantine Mitsiades MD, DFCI, Teru Hideshima, Nikhil C. Munshi, Paul G. Richardson and Kenneth C. AndersonThe P13 Kinase/AKT Pathway As A therapeutic Target for Multiple Myeloma Donald Harvey, PharmD, Jeanine Silberman, MD and Sagar Lonial MDThe Mammalian Target of Rapamycin (mTOR) and Multiple Myeloma Patrick Frost, PhD Alan Lichtenstein, MDCDK Inhibitors In Multiple Myeloma Yun Dai and Steven Grant MD, MCVFibroblast growth factor receptor 3 (FGFR3) and Multiple Myeloma (MM) Victor Hugo Jimenez-Zepeda, MD and Keith Stewart MDHistone Deacetylase Inhibitors In Multiple Myeloma Teru Hideshima MD, PhD, DFCIDeath Receptors In Multiple Myeloma and Therapeutic Opportunities, F. Mollinedo, PhDProteasome Inhibitors as Therapy in Multiple Myeloma Dharminder Chauhan PhD, Ajita Singh, PhD and Kenneth Anderson, MDSection 6: Supportive CarePathophysiology of Bone Disease in Multiple Myeloma Tomer M. Mark, MD and Roger N. Pearse MD, PhD Anemia and Erythropoeitic Growth Factors in Multiple Myeloma N Raje MD, DFCIPercutaneous Vertebroplasty and Balloon Kyphoplasty for the Treatment of Acute Painful Pathologic and Non-Pathologic Fractures Sandra Narayanan, MD and Frank Tong MDThe Role of Anatomic and